NYSE: LHLaboratory Corp Of America Holdings Stock
$216.98+4.54 (+2.14%)
Updated Jun 2, 2023
LH Price
$216.98
Fair Value Price
N/A
Market Cap
$19.22B
52 Week Low
$200.32
52 Week High
$263.13
P/E
19.43x
P/B
1.86x
P/S
1.38x
PEG
0.39x
Dividend Yield
1.33%
Revenue
$14.76B
Earnings
$1.00B
Gross Margin
28%
Operating Margin
9.54%
Profit Margin
6.8%
Debt to Equity
0.95
Operating Cash Flow
$2B
Beta
0.92
Next Earnings
Jul 26, 2023
Ex-Dividend
May 17, 2023
Next Dividend
Jun 8, 2023
LH Overview
Laboratory Corporation of America Holdings, a clinical laboratory company, offers tests (blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests). The company also provides gene-based and esoteric testing, and advanced tests targeting specific diseases. LabCorp was founded in 1971 and is headquartered in Burlington, NC.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LH ($216.98) is trading below its intrinsic value of $261.02, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LH is good value based on its earnings relative to its share price (19.43x), compared to the US market average (52.69x)
P/E vs Market Valuation
LH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more LH due diligence checks available for Premium users.
Be the first to know about important LH news, forecast changes, insider trades & much more!
LH News
Valuation
LH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
19.43x
Industry
31.67x
Market
52.69x
LH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
LH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
LH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.86x
Industry
4.02x
LH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LH price to earnings growth (PEG)
For valuing profitable companies with growth potential
LH is good value based... subscribe to Premium to read more.
PEG Value Valuation
LH's financial health
Profit margin
Revenue
$3.8B
Net Income
$212.9M
Profit Margin
5.6%
LH's Earnings (EBIT) of $1.41B... subscribe to Premium to read more.
Interest Coverage Financials
LH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.2B
Liabilities
$9.8B
Debt to equity
0.95
LH's short-term assets ($4.70B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LH's long-term liabilities ($6.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$121.2M
Investing
-$99.7M
Financing
-$60.6M
LH's operating cash flow ($1.72B)... subscribe to Premium to read more.
Debt Coverage Financials
LH vs Diagnostic & Research Stocks
Laboratory Of America Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.